Treatment of severe lichen planus with the JAK inhibitor tofacitinib

J Allergy Clin Immunol. 2020 Jun;145(6):1708-1710.e2. doi: 10.1016/j.jaci.2020.01.031. Epub 2020 Feb 1.

Authors

William Damsky¹, Alice Wang¹, Brianna Olamiju¹, Danielle Peterson¹, Anjela Galan², Brett King³

Affiliations

¹ Department of Dermatology, Yale School of Medicine, New Haven, Conn.
² Department of Dermatology, Yale School of Medicine, New Haven, Conn; Department of Pathology, Yale School of Medicine, New Haven, Conn.
³ Department of Dermatology, Yale School of Medicine, New Haven, Conn. Electronic address: brett.king@yale.edu.

PMID: 32018031
DOI: 10.1016/j.jaci.2020.01.031

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Female
Humans
Janus Kinase Inhibitors / therapeutic use*
Keratinocytes / drug effects
Keratinocytes / metabolism
Lichen Planus / drug therapy*
Lichen Planus / metabolism*
Male
Middle Aged
Mouth Mucosa / drug effects
Mouth Mucosa / metabolism
Piperidines / therapeutic use*
Pyrimidines / therapeutic use*
STAT Transcription Factors / metabolism
Signal Transduction / drug effects

Substances

Janus Kinase Inhibitors
Piperidines
Pyrimidines
STAT Transcription Factors
tofacitinib